3-甲酰基-1H-吲哚-7-羧酸 | 317854-65-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-甲酰基-1H-吲哚-7-羧酸
• 中文别名: 7-羧基吲哚-3-甲醛
• 英文名称: 3-formyl-1H-indole-7-carboxylic acid
• 英文别名: 3-formyl-indole-7-carboxylic acid
• CAS: 317854-65-2
• 化学式: C₁₀H₇NO₃
• mdl: MFCD00550642
• 分子量: 189.17
• InChiKey: HABYJDPNVBUDGD-UHFFFAOYSA-N

物化性质

• 熔点：
  308 °C
• 沸点：
  496.9±25.0 °C(Predicted)
• 密度：
  1.500±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 安全说明：
  S26,S37/39

SDS

Name:	3-Formyl-1h-indole-7-carboxylic acid 95+% Material Safety Data Sheet
Synonym:	7-Carboxyindole-3-carboxaldehyd
CAS:	317854-65-2

Section 1 - Chemical Product MSDS Name:3-Formyl-1h-indole-7-carboxylic acid 95+% Material Safety Data Sheet
Synonym:7-Carboxyindole-3-carboxaldehyd

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
317854-65-2	3-Formyl-1H-indole-7-carboxylic acid	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Air sensitive.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container. Store in a dry area. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 317854-65-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 305 deg C(decom)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H7NO3
Molecular Weight: 189

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to air.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 317854-65-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Formyl-1H-indole-7-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 317854-65-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 317854-65-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 317854-65-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲酰基-1H-吲哚-7-羧酸 在 三乙酰氧基硼氢化钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 76.0h， 生成 (4-isopropyl-piperazin-1-yl)-(3-morpholin-4-ylmethyl-1H-indol-7-yl)-methanone
  参考文献：
  名称：

  WO2008/109333

  摘要：

  公开号：
• 作为产物：
  描述：

  1H-吲哚-7-羧酸甲酯 在 lithium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 3-甲酰基-1H-吲哚-7-羧酸
  参考文献：
  名称：

  NAN“地址”部分的结构改变导致发现一种可降低 hERG 毒性的新型阿片受体调节剂

  摘要：

  寻找具有所需药理效力和改善安全性的选择性阿片类配体一直是人们感兴趣的领域。我们之前的努力产生了一种有效的阿片类调节剂 NAN，一种 6α- N -7'-吲哚基取代的纳曲胺衍生物，在体外和体内均表现出有前景的药理活性。然而，人类以太相关基因（hERG）的重大责任限制了其进一步发展。因此，对NAN进行了系统的结构修饰，以减轻hERG毒性，同时保留药理特性，从而发现了2'-甲基吲哚基衍生化合物21。与 NAN 相比，化合物21表现出整体改善的药理学特征。后续 hERG 通道抑制评估显示，与 NAN 相比，化合物21的效力降低了七倍。此外，一些基本的类药特性评估表明合理的 ADME 概况为21。总的来说，化合物21似乎是一种有前途的阿片类调节剂，可进一步开发为阿片类药物使用障碍治疗的新型治疗剂。

  DOI：

  10.1021/acs.jmedchem.2c01499

文献信息

• PPAR active compounds
  申请人：Arnold James

  公开号：US20080096913A1

  公开（公告）日：2008-04-24

  Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

  描述了对PPARs活性的化合物，包括全谱活性化合物。还描述了开发或鉴定具有所需选择性配置文件的化合物的方法。
• PPAR ACTIVE COMPOUNDS
  申请人：Arnold James

  公开号：US20070149603A1

  公开（公告）日：2007-06-28

  Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

  描述了对PPARs有活性的化合物，包括全谱活性化合物。还描述了开发或识别具有所需选择性配置文件的化合物的方法。
• INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR
  申请人：Allison Brett D.

  公开号：US20110178062A1

  公开（公告）日：2011-07-21

  Certain substituted indole and benzothiophene compounds are histamine H 3 receptor modulators useful in the treatment of histamine H 3 receptor-mediated diseases.

  某些取代的吲哚和苯并噻吩化合物是组胺H3受体调节剂，可用于治疗组胺H3受体介导的疾病。
• DNA-ENCODED CHEMICAL LIBRARY, USE THEREOF, AND METHOD TO SYNTHESIZE THE LIBRARY
  申请人：Technische Universität Dortmund

  公开号：EP3885437A1

  公开（公告）日：2021-09-29

  The present invention relates to a compound library comprising a plurality of conjugate molecules, wherein said conjugates comprise a small organic molecule covalently coupled to a nucleic acid moiety, wherein the nucleic acid moiety comprises or consists of 7-deazapurines and/or 7-deaza-8-azapurines, and, optionally, modified and/or unmodified pyrimidine nucleotides. Further, the present invention relates to the use of said library for screening compounds binding to a target molecule and methods of synthesizing said library.

  本发明涉及一种由多个共轭分子组成的化合物库，其中所述共轭分子包括与核酸分子共价偶联的小有机分子，所述核酸分子包括或由7-脱氮杂嘌呤和/或7-脱氮杂-8-氮杂嘌呤组成，以及可选的修饰和/或未修饰的嘧啶核苷酸。此外，本发明还涉及使用所述文库筛选与靶分子结合的化合物以及合成所述文库的方法。
• Use of indole compounds for fat reduction and skin and soft tissue tightening
  申请人：Alevere Medical Corporation

  公开号：US10258605B2

  公开（公告）日：2019-04-16

  The present invention relates to indole compounds and compositions and uses thereof, including uses of the indole compounds and compositions for the reduction or removal of localized fat deposits and/or tightening of skin and soft tissue laxity in subjects. The indole compounds can be employed, for example, in the cosmetic sector or for producing pharmaceutical products.

  本发明涉及吲哚化合物和组合物及其用途，包括吲哚化合物和组合物用于减少或去除局部脂肪沉积和/或收紧受试者的皮肤和软组织松弛。例如，吲哚化合物可用于化妆品行业或生产医药产品。